NI
UTHR icon

Nepsis Inc’s United Therapeutics UTHR Stock Holding History

Nepsis Inc’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Sell
27,273
-14,921
-35% -$8.4M 5.01% 9
2026
Q1 		$25M Sell
42,194
-1,566
-4% -$780K 8.38% 1
2025
Q4 		$21.3M Sell
43,760
-656
-1% -$305K 6.59% 1
2025
Q3 		$18.6M Sell
44,416
-3,356
-7% -$1.13M 5.9% 1
2025
Q2 		$13.7M Sell
47,772
-10,802
-18% -$3.23M 3.82% 15
2025
Q1 		$18.1M Buy
58,574
+3,653
+7% +$1.25M 4.46% 9
2024
Q4 		$19.4M Buy
54,921
+3,113
+6% +$1.14M 4.84% 10
2024
Q3 		$18.6M Buy
+51,808
New +$17.5M 4.4% 10

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Nepsis Inc's UTHR Position: Q2 2026 in Review

Nepsis Inc reduced its United Therapeutics (UTHR) stake by 35% in Q2 2026, selling an estimated $8.4M and leaving 27,273 shares worth $14.8M. The position accounts for 5.01% of the portfolio, ranked #9.

Nepsis Inc first reported a position in UTHR in Q3 2024 and has held it in 8 quarters since. The position peaked at $25M in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Nepsis Inc held 27,273 shares of United Therapeutics worth $14.8M as of Q2 2026.
  • Nepsis Inc sold 14,921 United Therapeutics shares in Q2 2026, an estimated $8.4M.
  • United Therapeutics made up 5.01% of Nepsis Inc's portfolio in Q2 2026, its #9 holding.
  • Nepsis Inc first reported a position in United Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Nepsis Inc's United Therapeutics position peaked at $25M in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Nepsis Inc's 13F filing for Q2 2026, filed 14 Jul 2026.